G

    GeoVax Labs Inc (GOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.63
    -0.09 (-12.29%)

    Market Cap: $3.76M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(26/33)
    Avg Surprise
    +52.54%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.09
    Range$-1.09 - $-1.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.48+55.5%
    60d ago$-2.12-94.5%
    30d ago$-2.12-94.5%
    7d ago$-2.12-94.5%
    Current$-1.09
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-1.05
    Range$-1.05 - $-1.05
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.05---
    Sep 26EST
    		-$-1.09---
    Jun 26
    		$-0.97N/A+55.09%Beat+88.9%
    Mar 26
    		$-2.62$-0.84-211.90%Miss+76.7%
    Dec 25
    		$N/A$-5.35N/ABeat-
    Sep 25
    		$-7.75$-6.62-17.07%Miss+65.9%
    Jun 25
    		$-8.75$-9.00+2.78%Beat+82.4%
    Mar 25
    		$-11.25$-16.44+31.57%Beat-355.5%
    Dec 24
    		$-0.30N/A+60.94%Beat+99.7%
    Sep 24
    		$-22.75$-32.90+30.85%Beat+81.0%
    Jun 24
    		$-49.75$-84.12+40.86%Beat+39.7%
    Mar 24
    		$-2.47N/A+55.58%Beat+95.6%
    Dec 23
    		$-98.50$-105.00+6.19%Beat-49150.0%
    Sep 23
    		$-120.00$-90.00-33.33%Miss-88.2%
    Jun 23
    		$-82.50$-63.75-29.41%Miss-22.2%
    Mar 23
    		$-56.25$-84.37+33.33%Beat+55.9%
    Dec 22
    		$-0.20$-0.20+0.00%Beat+91.0%
    Sep 22
    		$-63.75$-45.00-41.67%Miss+45.2%
    Jun 22
    		$-67.50$-112.50+40.00%Beat+14.3%
    Mar 22
    		$-127.50$-116.25-9.68%Miss-43865.5%
    Dec 21
    		$-2.23$-0.40-457.50%Miss-100.8%
    Sep 21
    		$-116.25$-138.75+16.22%Beat-15824.7%
    Jun 21
    		$-78.75N/A+51.16%Beat-262400.0%
    Mar 21
    		$-0.29$-0.29+0.00%Beat-123.1%
    Dec 20
    		$266.25$-15.00+1875.00%Beat+10665.5%
    Sep 20
    		$-0.73$-0.73+0.00%Beat+100.0%
    Jun 20
    		$-0.03$-0.03+0.00%Beat+100.0%
    Mar 20
    		$-0.13$-0.13+0.00%Beat+100.0%
    Dec 19
    		$-2.52N/A+99.76%Beat+100.0%
    Sep 19
    		$-449999.77N/A+55.00%Beat-22592518.2%
    Jun 19
    		$-1000000.00$-1000000.00+0.00%Beat-48728094.1%
    Mar 19
    		$-57200.00N/AN/ABeat+71.4%
    Dec 18
    		$-1000000.00N/AN/ABeat-400.0%
    Sep 18
    		$-1.99N/AN/ABeat+100.0%
    Jun 18
    		$-2.05N/AN/ABeat+100.0%
    Mar 18
    		$-200000.00N/AN/ABeat-1999999900.0%
    Dec 17
    		$-200000.00N/A+80.00%Beat+80.0%
    Sep 17
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 17
    		$-1000000.00$-1000000.00+0.00%Beat-
    Mar 17
    		$-0.01N/AN/ABeat-
    Dec 16
    		$-1000000.00$-1000000.00+0.00%Beat-
    Sep 16
    		$-1000000.00$-1000000.00+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.03EV/EBITDA15.26x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-892.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.54xQuick Ratio1.54x
    Trading Statistics
    Beta3.66Avg Volume1.18M
    52-Week High$19.2052-Week Low$0.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.65
    SMA 20$0.69
    SMA 50$0.90
    SMA 200$2.81
    EMA 10$0.67
    EMA 20$0.71
    EMA 50$0.92
    EMA 200$4.51

    MACD

    Line: -0.07Signal: -0.09Hist: 0.02

    ADX

    ADX: 24.9+DI: 25.3-DI: 24.3

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down68.0
    PSAR$0.88

    Bollinger Bands

    Upper Band$0.81
    Lower Band$0.58
    %B Position3268%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    39.2

    Momentum Oscillators

    Stoch %K34.9
    Stoch %D32.2
    Williams %R-85.2
    ROC (10d)-3.5%
    Momentum-0.02
    CCI (20d)-94.2
    MFI (14d)31.1

    Volatility Measures

    ATR (14d)$0.10(15.5%)
    StdDev (20d)0.06
    Hist Vol100.2%(High)

    Volume Flow

    VWAP$0.63
    OBV224.6M
    AD Line120.3B
    CMF (20d)-0.572

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.5x
    VWMA (20d)$0.64

    Pivot Points

    R3$0.79
    R2$0.76
    R1$0.74
    Pivot Point$0.71
    S1$0.69
    S2$0.66
    S3$0.64

    Advanced Oscillators

    TSI-24.17
    Ultimate Osc38.1
    KST-234.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$852,282$1.64M$864,415$2.79M$300,677$0$103,912$0
    Cost of Revenue$0$0N/A$0$0$0$21,641$0$0$0$22,213$0
    Gross Profit$0$0N/A$0$852,282$1.64M$864,415$2.79M$300,677$0$-22,213$0
    Operating Expenses$4.44M$5.27M$4.44M$6.37M$6.27M$7.04M$9.21M$8.64M$5.36M$5.88M$7.69M$8.60M
    R&D$3.11M$3.90M$2.99M$5.04M$4.73M$5.35M$7.61M$7.40M$4.28M$4.43M$6.23M$6.95M
    SG&A$1.33M$1.37M$1.45M$1.33M$1.54M$1.69M$1.60M$1.24M$1.09M$1.46M$1.46M$1.65M
    Operating Income$-4,442,072$-5,272,881$-4,441,756$-6,373,215$-5,418,906$-5,405,170$-8,344,402$-5,854,576$-5,062,221$-5,883,081$-7,693,750$-8,599,754
    Interest Income$15,494$10,960$23,333$54,301$49,123$47,519$81,748$53,191$5,471$32,949$101,342$190,936
    Interest Expense$0$0$0$0$0$0$0$14,083$7,292$0$0$0
    Income Before Tax$-4,426,578$-5,261,921$-4,418,423$-6,318,914$-5,369,783$-5,357,651$-8,262,654$-5,815,468$-5,064,042$-5,850,132$-7,592,408$-8,408,818
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,426,578$-5,261,921$-4,418,423$-6,318,914$-5,369,783$-5,357,651$-8,262,654$-5,815,468$-5,064,042$-5,850,132$-7,592,408$-8,408,818
    EBITDA$-4,429,996$-5,260,805$-4,423,526$-6,356,413$-5,402,103$-5,388,249$-8,322,761$-5,824,168$-5,038,478$-5,863,505$-7,671,537$-8,582,435
    EBIT$-4,442,072$-5,272,881$-4,441,756$-6,373,215$-5,418,906$-5,405,170$-8,344,402$-5,854,576$-5,062,221$-5,883,081$-7,693,750$-8,599,754
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GOVX

    News

    GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation

    GeoVax Labs, Inc. announced the selection of a contract research organization and European clinical trial sites for its pivotal Phase 3 study (GEO-MVA-301) of GEO-MVA, a vaccine against mpox and smallpox. This marks a significant step towards the immunobridging study, planned to enroll 500 healthy adults and compare GEO-MVA to a licensed MVA vaccine, with initiation in Q4 2026 and results by mid-2027. The company aims for EMA approval based on non-inferiority to address global needs for orthopoxvirus vaccine supply.

    TradingView•8/25/26•
    Bullish

    GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak

    GeoVax has initiated outreach to global public health organizations, including the WHO and Africa CDC, regarding its Ebola vaccine portfolio. This outreach is prompted by an expanding Ebola outbreak caused by the Bundibugyo virus and recent scientific evidence suggesting potential cross-protection from Zaire Ebola vaccines. The company is seeking evaluation and potential development paths for its MVA-based hemorrhagic fever vaccine candidates, particularly its Zaire Ebola vaccine candidate GEO-EM01, while maintaining its primary focus on its mpox and smallpox vaccine program, GEO-MVA.

    Yahoo Finance•8/24/26•
    Bullish

    GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit

    GeoVax's Chairman and CEO, David Dodd, is set to participate in the 2026 Georgia Life Sciences Summit. He will be featured in a "CEO Spotlight" presentation, discussing GeoVax's strategic decisions and evolution as a biotechnology company, and will also join a private roundtable with U.S. Representative Rich McCormick to discuss global health policy and innovation. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, with key programs including a vaccine candidate for mpox and smallpox, and a gene-directed therapy for solid tumors.

    Yahoo! Finance Canada•8/20/26•
    Bullish

    GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit

    GeoVax Labs, Inc. announced that its Chairman, President, and CEO, David Dodd, will participate in the 2026 Georgia Life Sciences Summit. Dodd will be featured in "CEO Spotlights" to discuss GeoVax's evolution and strategic decisions, as well as participate in a private roundtable with U.S. Representative Rich McCormick to discuss Georgia's role in global health and biotechnology policy. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer.

    The Globe and Mail•8/20/26•
    Somewhat-Bullish

    GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit

    GeoVax Labs, Inc.'s Chairman and CEO, David Dodd, will participate in the 2026 Georgia Life Sciences Summit, speaking at the "CEO Spotlights" event and a private roundtable with U.S. Representative Rich McCormick. Dodd will discuss GeoVax's strategic decisions in navigating the biotechnology landscape and contribute to discussions on global health policy and innovation. The summit aims to bring together leaders from industry, academia, and government to address key issues in the life sciences sector.

    Yahoo Finance•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About GOVX

    Does GOVX pay dividends?
    GeoVax Labs Inc (GOVX) does not currently pay a regular dividend.
    What is GOVX's market cap?
    GeoVax Labs Inc (GOVX) has a market capitalization of $3.76M with a current stock price of $0.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In